Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 487

1.

Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.

George DJ, Sartor O, Miller K, Saad F, Tombal B, Kalinovský J, Jiao X, Tangirala K, Sternberg CN, Higano CS.

Clin Genitourin Cancer. 2020 Jan 7. pii: S1558-7673(19)30392-1. doi: 10.1016/j.clgc.2019.12.019. [Epub ahead of print]

PMID:
32057714
2.

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B.

Ann Oncol. 2019 Dec;30(12):e3. doi: 10.1093/annonc/mdw180. No abstract available.

PMID:
32041688
3.

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.

Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A.

Eur Urol. 2020 Jan 27. pii: S0302-2838(20)30048-8. doi: 10.1016/j.eururo.2020.01.012. [Epub ahead of print]

4.

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.

Sternberg CN, Saad F, Graff JN, Peer A, Vaishampayan UN, Leung E, Rosenbaum E, Gurney H, Epstein RJ, Davis ID, Wu B, Trandafir L, Wagner VJ, Hussain M.

Ann Oncol. 2020 Feb;31(2):257-265. doi: 10.1016/j.annonc.2019.10.025. Epub 2019 Dec 23.

5.

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD; RISC Investigators.

Ann Oncol. 2019 Nov 1;30(11):1841. doi: 10.1093/annonc/mdz214. No abstract available.

PMID:
31868903
6.

Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.

Armstrong AJ, Al-Adhami M, Lin P, Parli T, Sugg J, Steinberg J, Tombal B, Sternberg CN, de Bono J, Scher HI, Beer TM.

JAMA Oncol. 2019 Dec 12. doi: 10.1001/jamaoncol.2019.4636. [Epub ahead of print]

7.

Ultrasmall TPGS-PLGA Hybrid Nanoparticles for Site-Specific Delivery of Antibiotics into Pseudomonas aeruginosa Biofilms in Lungs.

Wan F, Bohr SS, Kłodzińska SN, Jumaa H, Huang Z, Nylander T, Thygesen MB, Sørensen KK, Jensen KJ, Sternberg C, Hatzakis N, Mørck Nielsen H.

ACS Appl Mater Interfaces. 2020 Jan 8;12(1):380-389. doi: 10.1021/acsami.9b19644. Epub 2019 Dec 17.

PMID:
31804792
8.

Cross-Cultural Validity Study of a Medical Education Leadership Competencies Instrument in Latin American Physicians: A Multinational Study.

Mano MS, Gomes R, Werutsky G, Barrios CH, Marta GN, Villarreal-Garza C, Frasson AL, Sternberg C, Clara R, Simon SD, Çitaku F, Waldrop M, Violato C, Zillioux D, Khan YH.

J Glob Oncol. 2019 Nov;5:1-9. doi: 10.1200/JGO.19.00243.

9.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Bedke J, Gakis G, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Garcia Del Muro X, Rodriguez-Vida A, Cicin I, Harputluoglu H, Tagawa ST, Vaishampayan U, Aragon-Ching JB, Hamid O, Liepa AM, Wijayawardana S, Russo F, Walgren RA, Zimmermann AH, Hozak RR, Bell-McGuinn KM, Powles T; RANGE study investigators.

Lancet Oncol. 2020 Jan;21(1):105-120. doi: 10.1016/S1470-2045(19)30668-0. Epub 2019 Nov 18.

PMID:
31753727
10.

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.

Sternberg CN, Motzer RJ, Hutson TE, Choueiri TK, Kollmannsberger C, Bjarnason GA, Paul Nathan, Porta C, Grünwald V, Dezzani L, Han J, Tannir NM.

Clin Genitourin Cancer. 2019 Dec;17(6):425-435.e4. doi: 10.1016/j.clgc.2019.01.015. Epub 2019 Feb 6.

11.

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D; CARD Investigators.

N Engl J Med. 2019 Dec 26;381(26):2506-2518. doi: 10.1056/NEJMoa1911206. Epub 2019 Sep 30.

PMID:
31566937
12.

The arthroscopic triple-row modified suture bridge technique for rotator cuff repair: functional outcome and repair integrity.

Buckup J, Smolen D, Hess F, Sternberg C, Leuzinger J.

J Shoulder Elbow Surg. 2020 Feb;29(2):308-315. doi: 10.1016/j.jse.2019.06.010. Epub 2019 Aug 23.

PMID:
31451350
13.

Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.

Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC; RISC Investigators.

Eur Urol Oncol. 2019 Jan 30. pii: S2588-9311(19)30001-X. doi: 10.1016/j.euo.2018.12.013. [Epub ahead of print]

PMID:
31411990
14.

Application of a new polyester patch in arthroscopic massive rotator cuff repair-a prospective cohort study.

Smolen D, Haffner N, Mittermayr R, Hess F, Sternberg C, Leuzinger J.

J Shoulder Elbow Surg. 2020 Jan;29(1):e11-e21. doi: 10.1016/j.jse.2019.05.015. Epub 2019 Aug 9.

PMID:
31405714
15.

Utilizing nanoparticles for improving anti-biofilm effects of azithromycin: A head-to-head comparison of modified hyaluronic acid nanogels and coated poly (lactic-co-glycolic acid) nanoparticles.

Kłodzińska SN, Wan F, Jumaa H, Sternberg C, Rades T, Nielsen HM.

J Colloid Interface Sci. 2019 Nov 1;555:595-606. doi: 10.1016/j.jcis.2019.08.006. Epub 2019 Aug 3.

PMID:
31404843
16.

Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database.

Moschini M, Xylinas E, Zamboni S, Mattei A, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A; RISC Investigators.

Eur Urol Oncol. 2020 Feb;3(1):94-101. doi: 10.1016/j.euo.2019.06.014. Epub 2019 Jul 13.

PMID:
31307962
17.

Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.

Rescigno P, Dolling D, Conteduca V, Rediti M, Bianchini D, Lolli C, Ong M, Li H, Omlin AG, Schmid S, Caffo O, Zivi A, Pezaro CJ, Morley C, Olmos D, Romero-Laorden N, Castro E, Saez MI, Mehra N, Smeenk S, Sideris S, Gil T, Banks P, Sandhu SK, Sternberg CN, De Giorgi U, De Bono JS.

Eur Urol Oncol. 2019 Jul 12. pii: S2588-9311(19)30083-5. doi: 10.1016/j.euo.2019.06.008. [Epub ahead of print]

18.

Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.

Pederzoli F, Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Théodore C, Rosenberg JE, Harshman LC, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Necchi A; RISC Investigators.

Eur Urol. 2019 Oct;76(4):425-429. doi: 10.1016/j.eururo.2019.06.032. Epub 2019 Jul 11.

PMID:
31303258
19.

Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.

Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, Phung, Parli T, Krivoshik A, Beer TM.

Eur Urol Oncol. 2019 Nov;2(6):677-684. doi: 10.1016/j.euo.2018.11.005. Epub 2018 Dec 3.

20.

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study.

Attard G, Merseburger AS, Arlt W, Sternberg CN, Feyerabend S, Berruti A, Joniau S, Géczi L, Lefresne F, Lahaye M, Shelby FN, Pissart G, Chua S, Jones RJ, Tombal B.

JAMA Oncol. 2019 Jun 27. doi: 10.1001/jamaoncol.2019.1011. [Epub ahead of print] Erratum in: JAMA Oncol. 2019 Aug 1;5(8):1232.

21.

Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.

Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan U, Théodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A.

Eur Urol Oncol. 2019 May;2(3):248-256. doi: 10.1016/j.euo.2018.08.009. Epub 2018 Sep 7.

PMID:
31200838
22.

Somatic and germline sequencing in genitourinary oncology: genetics for the clinician.

Shoag JE, Wise DR, Sharaf RN, Sternberg CN.

Curr Opin Urol. 2019 Jul;29(4):315-318. doi: 10.1097/MOU.0000000000000643.

PMID:
31158105
23.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.

Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF.

Ann Oncol. 2019 Jun 1;30(6):970-976. doi: 10.1093/annonc/mdz127.

24.

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.

De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, Basso U, Mitterer M, Ortega C, Bidoli P, Ferraù F, Crinò L, Frassoldati A, Marchetti P, Mini E, Scoppola A, Verusio C, Fornarini G, Cartenì G, Caserta C, Sternberg CN.

Clin Cancer Res. 2019 Jul 1;25(13):3839-3846. doi: 10.1158/1078-0432.CCR-18-3661. Epub 2019 Apr 9.

PMID:
30967420
25.

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.

Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group.

J Immunother Cancer. 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z.

26.

The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.

Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U, Ladoire S, Theodore C, Agarwal N, Yu EY, Niegisch G, Sternberg CN, Srinivas S, Vaishampayan U, Necchi A, Liontos M, Rosenberg JE, Powles T, Bellmunt J, Galsky MD.

Oncologist. 2019 Oct;24(10):1348-1355. doi: 10.1634/theoncologist.2018-0739. Epub 2019 Apr 1.

27.

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.

Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U, Masini C, Bamias A, Garcia Del Muro X, Duran I, Powles T, Gamulin M, Zengerling F, Geczi L, Gedye C, de Ducla S, Fear S, Merseburger AS.

Eur Urol. 2019 Jul;76(1):73-81. doi: 10.1016/j.eururo.2019.03.015. Epub 2019 Mar 23.

28.

10 Years of Arthroscopic Latarjet Procedure: Outcome and Complications.

Meraner D, Smolen D, Sternberg C, Thallinger C, Hahne J, Leuzinger J.

Indian J Orthop. 2019 Jan-Feb;53(1):102-110. doi: 10.4103/ortho.IJOrtho_273_17.

29.

Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer.

Sternberg CN.

Future Oncol. 2019 May;15(13):1437-1457. doi: 10.2217/fon-2018-0940. Epub 2019 Mar 8. Review.

30.

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.

Tombal B, Saad F, Penson D, Hussain M, Sternberg CN, Morlock R, Ramaswamy K, Ivanescu C, Attard G.

Lancet Oncol. 2019 Apr;20(4):556-569. doi: 10.1016/S1470-2045(18)30898-2. Epub 2019 Feb 12.

PMID:
30770294
31.

Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.

Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ.

Future Oncol. 2019 Mar;15(9):929-941. doi: 10.2217/fon-2018-0745. Epub 2019 Jan 28.

32.

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database.

Del Bene G, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN.

Front Oncol. 2018 Nov 19;8:463. doi: 10.3389/fonc.2018.00463. eCollection 2018.

33.

Clinical Trials Corner.

Agarwal PK, Sternberg CN.

Bladder Cancer. 2018 Oct 29;4(4):447-449. doi: 10.3233/BLC-189040. No abstract available.

34.

Enzalutamide in Castration-Resistant Prostate Cancer.

Hussain M, Saad F, Sternberg CN.

N Engl J Med. 2018 Oct 4;379(14):1381. doi: 10.1056/NEJMc1810065. No abstract available.

PMID:
30281993
35.

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.

Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN.

World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20. Review.

PMID:
30238401
36.

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.

Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, Templeton AJ, Fizazi K, Phung D, Wong EK, Krivoshik A, Beer TM.

Ann Oncol. 2018 Nov 1;29(11):2200-2207. doi: 10.1093/annonc/mdy406.

37.

Clinical Trials Corner.

Agarwal PK, Sternberg CN.

Bladder Cancer. 2018 Jul 30;4(3):347-350. doi: 10.3233/BLC-189036. No abstract available.

38.

Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer.

Hugo de Almeida V, Guimarães IDS, Almendra LR, Rondon AMR, Tilli TM, de Melo AC, Sternberg C, Monteiro RQ.

Oncotarget. 2018 Jul 17;9(55):30594-30609. doi: 10.18632/oncotarget.25748. eCollection 2018 Jul 17.

39.

Synergistic cross-talk of hedgehog and interleukin-6 signaling drives growth of basal cell carcinoma.

Sternberg C, Gruber W, Eberl M, Tesanovic S, Stadler M, Elmer DP, Schlederer M, Grund S, Roos S, Wolff F, Kaur S, Mangelberger D, Lehrach H, Hache H, Wierling C, Laimer J, Lackner P, Wiederstein M, Kasper M, Risch A, Petzelbauer P, Moriggl R, Kenner L, Aberger F.

Int J Cancer. 2018 Dec 1;143(11):2943-2954. doi: 10.1002/ijc.31724. Epub 2018 Oct 1.

40.

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.

De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group.

BJU Int. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. Epub 2018 Jul 23.

41.

Clinical Trials Corner.

Agarwal PK, Sternberg CN.

Bladder Cancer. 2018 Apr 26;4(2):243-244. doi: 10.3233/BLC-189033. No abstract available.

42.

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, Krivoshik A, Sternberg CN.

N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.

43.

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, Sternberg CN, Pili R, Tuvesson H, Nordle Ö, Carducci MA, Morris MJ.

JAMA Oncol. 2018 Jul 1;4(7):944-951. doi: 10.1001/jamaoncol.2018.1093.

44.

The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.

Saad F, Sternberg CN, Mulders PFA, Niepel D, Tombal BF.

Cancer Treat Rev. 2018 Jul;68:25-37. doi: 10.1016/j.ctrv.2018.04.014. Epub 2018 May 3. Review.

45.

Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.

Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI, Larkin J, Pal SK, Powles T, Ryan CW, Sternberg CN, Uzzo R, Choueiri TK, Bex A.

Eur Urol. 2018 Nov;74(5):611-620. doi: 10.1016/j.eururo.2018.05.002. Epub 2018 May 18.

PMID:
29784193
46.

Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.

Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Cartenì G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E.

Clin Genitourin Cancer. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19.

PMID:
29753637
47.

Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica.

Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A, Bahleda R, Jamme P, Gelli M, Goere D, Lacroix L, Adam J, Heukamp L, Trenta P, Hembrough T, Soria JC, Sternberg C, Ducreux M.

Tumori. 2018 Dec;104(6):NP38-NP41. doi: 10.1177/0300891618763215. Epub 2018 Mar 21.

PMID:
29714649
48.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712
49.

Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.

Dos Santos Guimarães I, Ladislau-Magescky T, Tessarollo NG, Dos Santos DZ, Gimba ERP, Sternberg C, Silva IV, Rangel LBA.

Pharmacol Rep. 2018 Jun;70(3):409-417. doi: 10.1016/j.pharep.2017.11.007. Epub 2017 Nov 21.

PMID:
29627688
50.

Differential bacterial capture and transport preferences facilitate co-growth on dietary xylan in the human gut.

Leth ML, Ejby M, Workman C, Ewald DA, Pedersen SS, Sternberg C, Bahl MI, Licht TR, Aachmann FL, Westereng B, Abou Hachem M.

Nat Microbiol. 2018 May;3(5):570-580. doi: 10.1038/s41564-018-0132-8. Epub 2018 Apr 2.

PMID:
29610517

Supplemental Content

Loading ...
Support Center